The coordinated regulation of key players in angiogenesis such as HuR, HIF-1α, and VEGF-C suggest that upregulation of GRK2 might be a relevant event for acquiring increased malignancy and invasiveness, and point that combined pharmacological inhibition of GRK2 might be useful in certain cancer therapy contexts. The gene discussed is GRK2; the disease is cancer.